# Fulgent Genetics, Inc. (FLGT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/FLGT
## Company Profile
- Ticker: FLGT
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Oncology
## Stock Data
- Close: 19 USD
- Market cap: 531091650.09999996 USD
- Last updated: 2026-08-11
## Business Overview
### Precision Medicine Business
Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization.
### Laboratory Services
Fulgent provides technical laboratory testing and physician interpretation services. Its operations include genetic and specialty diagnostic capabilities serving healthcare providers, institutions and other customers.
### Oncology Therapeutics
The therapeutic business uses nanoencapsulation and targeted-delivery technology to improve the pharmacokinetics and therapeutic window of cancer drugs. Clinical candidates FID-007 and FID-022 represent the lead applications of this platform.
## Why The Stock Is Moving

As of Aug 11, 2026, FLGT closed down 0.31% at $19.00. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 2 FID-007 data in a rapid oral presentation at the 2026 ASCO Annual Meeting.

## Recent News
- 2026-07-30 20:05 EST — [Fulgent Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/FLGT/fulgent-reports-second-quarter-2026-financial-results-eedcdc21) — Source: Fulgent Genetics, Inc.
- 2026-07-09 20:05 EST — [Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026](https://biopharmsignal.com/news/FLGT/fulgent-to-announce-second-quarter-2026-financial-results-on-thursday-july-30-20-db6ce056) — Source: Fulgent Genetics, Inc.
- 2026-06-01 23:00 EST — [Fulgent Presents Updated FID-007 Data at ASCO 2026](https://biopharmsignal.com/news/FLGT/fulgent-presents-updated-fid-007-data-at-asco-2026) — Source: Fulgent Genetics, Inc.
- 2026-05-21 21:03 EST — [Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/FLGT/fulgent-announces-rapid-oral-full-abstract-publication-for-fid-007-within-the-head-and-neck-cancer-track-session-at-the-asco-2026-annual-meeting) — Source: Fulgent Genetics, Inc.
- 2026-05-01 11:00 EST — [Fulgent Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/FLGT/fulgent-reports-first-quarter-2026-financial-results) — Source: Fulgent Genetics, Inc.